Research progress in Ph-like childhood acute lymphoblastic leukemia
TANG Xue, GUO Xia
Department of Pediatrics, West China Second University Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Diseases of Women and Children(Sichuan University), Ministry of Education, Chengdu 610041, China
Abstract Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a subtype of B-lineage ALL (B-ALL) that displays a gene expression profile (GEP) similar to Philadelphia chromosome-positive ALL (Ph+ ALL). It has a diverse range of genetic alterations that activate cytokine receptor genes and kinase signaling pathways, frequently accompanied by abnormal transcription factors related to lymphatic development. Children with Ph-like ALL account for 15% of children with high-risk B-ALL. It has adverse clinical features and a poor prognosis. Tyrosine kinase inhibitors combined with chemotherapy can significantly improve the prognosis of children with Ph+ ALL, suggesting that targeted therapy based on the molecular cytogenetic abnormalities of Ph-like ALL has good research prospects. This paper expounds the genetic alterations, pathogenesis, clinical features, diagnostic measures, and potential therapeutic approaches of Ph-like childhood ALL based on recent research progress in Ph-like ALL.
Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children[J]. N Engl J Med, 2015, 373(16):1541-1552.
[2]
Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome:a genome-wide classification study[J]. Lancet Oncol, 2009, 10(2):125-134.
[3]
Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia[J]. N Engl J Med, 2009, 360(5):470-480.
[4]
Ofran Y, Izraeli S. BCR-ABL(Ph)-like acute leukemia-pathogenesis, diagnosis and therapeutic options[J]. Blood Rev, 2017, 31(2):11-16.
[5]
Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia[J]. N Engl J Med, 2014, 371(11):1005-1015.
[6]
Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia[J]. Blood, 2009, 114(13):2688-2698.
[7]
Chen IM, Harvey RC, Mulighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatirc acute lymphoblastic leukemia:a Children's Oncology Group study[J]. Blood, 2012, 119(15):3512-3522.
[8]
Yoda A, Yoda Y, Chiaretti S, et al. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia[J]. Proc Natl Acad Sci USA, 2010, 107(1):252-257.
[9]
Buitenkamp TD, Izraeli S, Zimmermann M, et al. Acute lymphoblastic leukemia in children with Down syndrome:a retrospective analysis from the Ponte di Legno study group[J]. Blood, 2014, 123(1):70-77.
[10]
Loh ML, Zhang J, Harvey RC, et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia:a report from the Children's Oncology Group TARGET Project[J]. Blood, 2013, 121(3):485-488.
[11]
Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia:insights and treatment implications[J]. Nat Rev Clin Oncol, 2015, 12(6):344-357.
[12]
Iacobucci I, Li Y, Roberts KG, et al. Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia[J]. Cancer Cell, 2016, 29(2):186-200.
[13]
Robert KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia[J]. Cancer Cell, 2012, 22(2):153-166.
[14]
Demoulin JB, Montano-Almendras CP. Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis[J]. Am J Blood Res, 2012, 2(1):44-56.
[15]
Kasyapa C, Gu TL, Nagarajan L, et al. Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS[J]. Proteomics, 2009, 9(16):3979-3988.
[16]
Churchman ML, Low J, Qu C, et al. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia[J]. Cancer Cell, 2015, 28(3):343-356.
[17]
Joshi I, Yoshida T, Jena N, et al. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia[J]. Nat Immunol, 2014, 15(3):294-304.
[18]
Witkowski MT, Hu Y, Roberts KG, et al. Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome[J]. J Exp Med, 2017, 214(3):773-791.
[19]
Schinnerl D, Fortschegger K, Kauer M, et al. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia[J]. Blood, 2015, 125(8):1282-1291.
[20]
Cheng Y, Chikwava K, Wu C, et al. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors[J]. J Clin Invest, 2016, 126(4):1267-1281.
[21]
Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse[J]. Nat Genet, 2013, 45(12):1494-1498.
[22]
Roberts KG, Gu Z, Prayne-Tuner D, et al. High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults[J]. J Clin Oncol, 2017, 35(4):394-401.
[23]
Roberts KG, Pei D, Campana D, et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease[J]. J Clin Oncol, 2014, 32(27):3012-3020.
[24]
Schwab C, Ryan SL, Chilton L, et al. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL):genetic profile and clinical implications[J]. Blood, 2016, 127(18):2214-2218.
[25]
Yap KL, Furtado LV, Kiyotani K, et al. Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL)[J]. Leuk Lymphoma, 2017, 58(4):950-958.
[26]
Ishibashi T, Yaguchi A, Terada K, et al. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells[J]. Exp Hematol, 2016, 44(3):177-188.e5.
[27]
Lengline E, Beldjord K, Dombret H, et al. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion[J]. Haematologica, 2013, 98(11):e146-e148.
[28]
Weston BW, Hayden MA, Roberts KG, et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia[J]. J Clin Oncol, 2013, 31(25):e413-e416.
[29]
Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia[J]. Blood, 2012, 120(17):3510-3518.
[30]
Kobayashi K, Miyagawa N, Mitsui K, et al. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation[J]. Pediatr Blood Cancer, 2015, 62(6):1058-1060.
[31]
Tasian SK, Doral MY, Borowitz MJ, et al. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia[J]. Blood, 2012, 120(4):833-842.
[32]
Waibel M, Solomon VS, Knight DA, et al. Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors[J]. Cell Rep, 2013, 5(4):1047-1059.
[33]
Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition[J]. Blood, 2014, 124(23):3420-3430.
[34]
Tasian SK, Teachey DT, Li Y, et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia[J]. Blood, 2017, 129(2):177-187.
[35]
Zaliova M, Moorman AV, Cazzaniga G, et al. Characterization of leukemias with ETV6-ABL1 fusion[J]. Haematologica, 2016, 101(9):1082-1093.
[36]
Weigert O, Lane AA, Bird L, et al. Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition[J]. J Exp Med, 2012, 209(2):259-273.
[37]
Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias[J]. Blood. 2015, 126(22):2479-2483.
[38]
Churchman ML, Low J, Qu C, et al. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia[J]. Cancer Cell, 2015, 28(3):343-356.